Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hirsh, J.
space
  arrow  Bates, S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REPLY

Questioning the Treatment of Venous Thromboembolism

right arrow Jack Hirsh, MD, FRCP(C), and Shannon Bates, MDCM, FRCP(C)

16 July 2002 | Volume 137 Issue 2 | Page 145


IN RESPONSE:

Our article discussed clinical trials that have influenced practice. The study by Barritt and Jordan (1) did so and was of historical importance. Barritt and Jordan found that in patients who were considered to have pulmonary embolism, 5 of 19 who did not receive anticoagulants died compared with 0 of 16 who did. This difference was statistically significant (P = 0.036). Several subsequent randomized trials (2-4) have supported Barritt and Jordan's contention that anticoagulants are indicated to treat patients with venous thromboembolism.

The study by Nielsen and colleagues (5) is interesting but did not influence practice. The authors themselves stated, "[T]he patient population ... is relatively small with wide confidence intervals for differences between groups. Before more general recommendations can be made, a large-scale placebo-controlled study is needed to evaluate the possible effect of [anticoagulant] treatment in DVT patients who can be mobilized from the first day." It should also be noted that the relative risk for progression of proximal venous thrombosis in this study was almost 40% greater in phenylbutazone-treated patients than in anticoagulant-treated patients.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Hamilton Civic Hospitals Research Centre; Hamilton, Ontario L8V 1C3, Canada (Hirsh)
McMaster University Medical Centre; Hamilton, Ontario L8N 3Z5, Canada (Bates)


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial Lancet. 1960;1:1309-12.

2. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis Lancet. 1985;2:515-8. [PMID: 2863541].

3. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis N Engl J Med. 1979;301:855-8. [PMID: 384248].[Abstract]

4. Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N Engl J Med. 1992;327:1485-9. [PMID: 1406880].[Abstract]

5. Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen HH, et al. Anticoagulant therapy in deep venous thrombosis. A randomized controlled study Thromb Res. 1994;73:215-26. [PMID: 8191414].

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.


Related articles in Annals:

History of Medicine
Clinical Trials That Have Influenced the Treatment of Venous Thromboembolism: A Historical Perspective
Jack Hirsh AND Shannon M. Bates
Annals 2001 134: 409-417. [ABSTRACT][Full Text]  

Brief Communications
The Reliability of Medical Record Review for Estimating Adverse Event Rates
Eric J. Thomas, Stuart R. Lipsitz, David M. Studdert, AND Troyen A. Brennan
Annals 2002 136: 812-816. [ABSTRACT][SUMMARY][Full Text]  

Letters
Questioning the Treatment of Venous Thromboembolism
David K. Cundiff
Annals 2002 137: 144-145. [Full Text]  




box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hirsh, J.
space
  arrow  Bates, S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online